Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

An afternoon dose also yielded significantly better overnight (10 p.m. to 4 a.m.) suppression in blood eosinophil counts as a ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Asthma Drugs Market Oral and injectable forms are expanding, especially for patients with severe asthma and those undergoing biologic treat ...

England’s cost effectiveness body NICE has recommended GSK’s new severe asthma treatment Nucala, reversing an earlier decision to reject it. Nucala (mepolizumab) is the first biologic ...

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

In recent winters, doctors have warned of a potential “ tripledemic ”—a surge of three major respiratory illnesses at once.

Inflammatory markers boosted asthma attack prediction, potentially allowing intensification of treatment, according to a meta ...

Long-term treatment with mepolizumab, an interleukin-5 inhibitor, demonstrates a favorable safety profile and sustained corticosteroid-sparing benefits among patients with eosinophilic granulomatosis ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...